Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Variability in NSAID Response
NCT02502006Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Nov 2015
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of celecoxib and naproxen (2 cohorts), sponsored by University of Pennsylvania. Primary endpoints: Cyclooxygenase-1 Activity ex Vivo at 12 hours, Cyclooxygenase-2 Activity ex Vivo at 12 hours and 2 more. Started Nov 2015; status: terminated.
02
Drugs
celecoxibnaproxen
Beyond the preview
Go deeper on NCT02502006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502006.